Repository logo
 

A plasma metabolite score of three eicosanoids predicts incident type 2 diabetes: a prospective study in three independent cohorts.

Published version
Peer-reviewed

Type

Article

Change log

Authors

Long, Tao 
Watrous, Jeramie D 
Mercader, Kysha 

Abstract

INTRODUCTION: Peptide markers of inflammation have been associated with the development of type 2 diabetes. The role of upstream, lipid-derived mediators of inflammation such as eicosanoids, remains less clear. The aim of this study was to examine whether eicosanoids are associated with incident type 2 diabetes. RESEARCH DESIGN & METHODS: In the FINRISK (Finnish Cardiovascular Risk Study) 2002 study, a population-based sample of Finnish men and women aged 25-74 years, we used directed, non-targeted liquid chromatography-mass spectrometry to identify 545 eicosanoids and related oxylipins in the participants' plasma samples (n=8292). We used multivariable-adjusted Cox regression to examine associations between eicosanoids and incident type 2 diabetes. The significant independent findings were replicated in the Framingham Heart Study (FHS, n=2886) and DIetary, Lifestyle and Genetic determinants of Obesity and Metabolic syndrome (DILGOM) 2007 (n=3905). Together, these three cohorts had 1070 cases of incident type 2 diabetes. RESULTS: In the FINRISK 2002 cohort, 76 eicosanoids were associated individually with incident type 2 diabetes. We identified three eicosanoids independently associated with incident type 2 diabetes using stepwise Cox regression with forward selection and a Bonferroni-corrected inclusion threshold. A three-eicosanoid risk score produced an HR of 1.56 (95% CI 1.41 to 1.72) per 1 SD increment for risk of incident diabetes. The HR for comparing the top quartile with the lowest was 2.80 (95% CI 2.53 to 3.07). In the replication analyses, the three-eicosanoid risk score was significant in FHS (HR 1.24 (95% CI 1.10 to 1.39, p<0.001)) and directionally consistent in DILGOM (HR 1.12 (95% CI 0.99 to 1.27, p=0.07)). Meta-analysis of the three cohorts yielded a pooled HR of 1.31 (95% CI 1.05 to 1.56). CONCLUSIONS: Plasma eicosanoid profiles predict incident type 2 diabetes and the clearest signals replicate in three independent cohorts. Our findings give new information on the biology underlying type 2 diabetes and suggest opportunities for early identification of people at risk.

Description

Keywords

diabetes mellitus, type 2, eicosanoids, epidemiology, inflammation, Adult, Aged, Diabetes Mellitus, Type 2, Eicosanoids, Female, Humans, Male, Metabolic Syndrome, Middle Aged, Prospective Studies, Risk Factors

Journal Title

BMJ Open Diabetes Res Care

Conference Name

Journal ISSN

2052-4897
2052-4897

Volume Title

10

Publisher

BMJ
Sponsorship
Academy of Finland (321356, 46558, 321351, 141136)
Department of Medicine, Boston University School of Medicine (Evans Scholar award and Jay and Louis Coffman Foun)
Framingham Heart Study (N01-HC-25195, 75N92019D00031, HHSN268201500001I)
NHLBI NIH HHS (N01HC25195, HHSN268201500001I, 75N92019D00031, HHSN268201500001C)
National Institutes of Health (S10OD020025, R01ES027595, K01DK116917)
Finnish Foundation for Cardiovascular Research (N/A)
Finnish Medical Foundation (N/A)
NIH HHS (S10 OD020025)
NIDDK NIH HHS (K01 DK116917)
Eli Lilly Finland (N/A)
Emil Aaltonen Foundation (N/A)
The Future Forum, Astra Zeneca (N/A)
Paavo Nurmi Foundation (N/A)
Social Insurance Institution of Finland (N/A)
Aarne Koskelo Foundation (N/A)
NIEHS NIH HHS (R01 ES027595)